OncoMatch/Clinical Trials/NCT02290145

Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage

Is NCT02290145 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TPF group for mouth neoplasms.

Phase 2RecruitingShanghai Jiao Tong University School of MedicineNCT02290145Data as of May 2026

Treatment: TPF group — The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: CCND1 high expression (high)

Disease stage

Required: Stage III, IVA

Performance status

KARNOFSKY 61–100

Karnofsky performance status (KPS) >60

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: surgery

Exception: diagnostic biopsy

Surgical procedure of the primary tumors or lymph nodes (except diagnostic biopsy)

Cannot have received: radiation therapy

Previous radiotherapy

Cannot have received: cytotoxic chemotherapy

Previous chemotherapy

Lab requirements

Blood counts

white blood cell >3,000/mm3, hemoglobin >8g/L, platelet count >80,000/mm3

Kidney function

serum creatinine <1.5x ULN; creatinine clearance <30ml/min [excluded]

Liver function

ALAT/ASAT <2.5x ULN, bilirubin <1.5x ULN

Adequate hematologic function: white blood cell >3,000/mm3, hemoglobin>8g/L, platelet count>80,000/mm3. Hepatic function: ALAT/ASAT <2.5x ULN, bilirubin <1.5x ULN. Renal function: serum creatinine <1.5x ULN. Creatinine clearance <30ml/min [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify